Related Experiment Video
Updated: Aug 16, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
Time Course of Coagulopathy Evaluated with Rotational Thromboelastometry in Patients with Severe Coronavirus Disease
Takeshi Yagi1, Motoki Fujita1, Kayoko Harada1
1Advanced Medical Emergency and Critical Care Center, Yamaguchi University Hospital, Japan.
Insights
Severe COVID-19 patients exhibit persistent hypercoagulability and worsening hypofibrinolysis from intensive care unit (ICU) admission to discharge. This indicates prolonged coagulopathy, impacting understanding of COVID-19
Area of Science:
- * Critical care medicine
- * Hematology
- * Infectious diseases
Background:
- * Coronavirus disease 2019 (COVID-19) is associated with thromboembolic events.
- * COVID-19-induced coagulopathy involves hypercoagulability and hypofibrinolysis.
- * Understanding the temporal course of coagulopathy in severe COVID-19 is crucial.
Purpose of the Study:
- * To evaluate the time-course of coagulopathy in severe COVID-19 patients.
- * To assess changes in coagulation parameters from ICU admission to discharge.
- * To investigate markers of hypercoagulability and hypofibrinolysis.
Main Methods:
- * Retrospective study of adult patients with severe COVID-19 admitted to the ICU.
- * Data collection included clinical information, laboratory results, and rotational thromboelastometry (ROTEM) parameters.
- * ROTEM parameters assessed at admission and discharge.
Main Results:
- * Fifteen patients were included in the analysis.
- * Fibrinogen and D-dimer levels remained elevated without significant change.
- * Maximum clot firmness (FIBTEM) indicated persistent hypercoagulability.
- * Markers of fibrinolysis (EXTEM, INTEM) significantly decreased at discharge, indicating worsening hypofibrinolysis.
Conclusions:
- * Severe COVID-19 patients demonstrate persistent hypercoagulability at ICU discharge.
- * A hypofibrinolytic state worsens from ICU admission to discharge.
- * Findings enhance understanding of coagulopathy during acute to subacute phases of severe COVID-19.
Abstract:
Objectives Coronavirus disease 2019 (COVID-19) reportedly causes thromboembolic complications due to coagulopathy with hypercoagulability and a hypofibrinolytic state. We evaluated the time-course of coagulopathy in patients with severe COVID-19 from admission to discharge from our intensive-care unit (ICU). Methods We conducted a retrospective study of adults with severe COVID-19 admitted to our ICU between January 20, 2021, and March 31, 2022. We obtained clinical information, laboratory data, and rotational thromboelastometry (ROTEM) parameters at admission and discharge. Results Fifteen patients were included. Fibrinogen and D-dimer values did not change significantly but were above the normal ranges at admission and discharge. Regarding ROTEM parameters, the maximum clot firmness in fibrinogen function (FIBTEM), a marker of hypercoagulability, did not change significantly but was above the normal range at admission and discharge [median (interquartile range), admission vs. discharge: 31 (25-34) mm vs. 31 (27-32) mm, p=0.589]. The maximum lysis at 60 minutes in the extrinsic coagulation pathway (EXTEM) and intrinsic coagulation pathway (INTEM), as markers of the fibrinolytic function, were both significantly lower at discharge than at admission [median (interquartile range), admission vs. discharge: EXTEM, 3 (2-4) vs. 1 (0-2), p=0.011; INTEM, 3 (1-6) vs. 1 (0-2), p=0.008]. Conclusion This study revealed a persistent hypercoagulable state at ICU discharge and a worse hypofibrinolytic state at discharge than at admission. These results may contribute to a better understanding of coagulopathies in the acute to subacute phases of severe COVID-19.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Coagulation
Pulmonary Embolism I: Introduction
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

